A ligand's view of target similarity: Chemogenomic binding site-directed techniques for drug discovery

Current Topics in Medicinal Chemistry

Volumn 11, Issue 15, 2011, Pages 1872-1881

  Garland, Stephen L ^a   Gloriam, David E ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

7TM; Chemogenomics; Compound library design; GPCR; Lead generation; Polypharmacology; Privileged structures; Selectivity

Indexed keywords

BENZIMIDAZOLE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; LIGAND; SOMATOSTATIN RECEPTOR 5;

BINDING SITE; BIOLOGY; CHEMISTRY; CHEMOGENOMICS; CORRELATION ANALYSIS; CORRELATIONAL STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; MOLECULAR EVOLUTION; PHARMACOGENOMICS; RECEPTOR BINDING; REVIEW; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, G-PROTEIN-COUPLED; SEQUENCE ALIGNMENT;

EID: 79960606839     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796391276     Document Type: Review

References (44)

1. Bondensgaard, K.; Ankersen, M.; Thøgersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P., Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem. 2004, 47 (4), 888-899.
2. Crossley, R., The design of screening libraries targeted at G-protein coupled receptors. Curr. Top. Med. Chem. 2004, 4 (6), 581-588.
3. Crossley, R.; Slater, M. J., A reductionist approach to chemogenomics in the design of drug molecules and focused libraries. In Chemogenomics Knowledge-based Approaches to Drug Discovery, Jacoby, E., Ed. Imperial College Press: London, 2006; pp 85-108.
4. Jimonet, P.; Jäger, R., Strategies for designing GPCR-focused libraries and screening sets. Current opinion in drug discovery & development 2004, 7 (3), 325-333.
5. Klabunde, T.; Giegerich, C.; Evers, A., Sequence-derived three- dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. J. Med. Chem. 2009, 52 (9), 2923-2932.
6. Bredel, M.; Jacoby, E., Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat.Rev.Genet. 2004, 5 (4), 262-275.
7. Jacoby, E., Designing Compound Libraries Targeting GPCRs. Ernst Schering Foundation Symposium Proceedings 2007, 2, 93-103.
8. Receveur, J.-M.; Bjurling, E.; Ulven, T.; Little, P. B.; Nørregaard, P. K.; Högberg, T., 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2004, 14 (20), 5075-5080.
9. Frimurer, T. M.; Ulven, T.; Elling, C. E.; Gerlach, L. O.; Kostenis, E.; Hogberg, T., A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg. Med. Chem. Lett. 2005, 15 (16), 3707-3712.
10. Martin, R. E.; Green, L. G.; Guba, W.; Kratochwil, N.; Christ, A., Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. J. Med. Chem. 2007, 50 (25), 6291-6294.
11. Guba, W.; Green, L. G.; Martin, R. E.; Roche, O.; Kratochwil, N.; Mauser, H.; Bissantz, C.; Christ, A.; Stahl, M., From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling. J. Med. Chem. 2007, 50 (25), 6295-6298.
12. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L. H.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L., Predicting new molecular targets for known drugs. Nature 2009, 462 (7270), 175-181.
13. Surgand, J.-S.; Rodrigo, J.; Kellenberger, E.; Rognan, D., A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 2006, 62 (2), 509-538.
14. Kratochwil, N. A.; Malherbe, P.; Lindemann, L.; Ebeling, M.; Hoener, M. C.; Mühlemann, A.; Porter, R. H. P.; Stahl, M.; Gerber, P. R., An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application. J. Chem Inf. Model. 2005, 45 (5), 1324-1336.
15. Jacoby, E.; Fauchère, J.-L.; Raimbaud, E.; Ollivier, S.; Michel, A.; Spedding, M., A Three Binding Site Hypothesis for the Interaction of Ligands with Monoamine G Protein-coupled Receptors: Implications for Combinatorial Ligand Design. Quant. Struct.-Act. Relat. 1999, 18 (6), 561-572.
16. Bywater, R. P., Location and nature of the residues important for ligand recognition in G-protein coupled receptors. Journal of molecular recognition: JMR 2005, 18 (1), 60-72.
17. Gloriam, D. E.; Foord, S. M.; Blaney, F. E.; Garland, S. L., Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem. 2009, 52 (14), 4429-4442.
18. Gloriam, D. E.; Garland, S. L., Chemogenomic Analysis Can Rationalise and Predict the Binding Profiles of Privileged Structures at GPCRs. Unpublished.
19. Fredriksson, R.; Lagerström, M. C.; Lundin, L.-G.; Schiöth, H. B., The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 2003, 63 (6), 1256-1272.
20. Gloriam, D. E.; Fredriksson, R.; Schiöth, H. B., The G protein-coupled receptor subset of the rat genome. BMC genomics 2007, 8, 338-338.
21. Lindemann, L.; Ebeling, M.; Kratochwil, N. A.; Bunzow, J. R.; Grandy, D. K.; Hoener, M. C., Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 2005, 85 (3), 372-385.
22. Lindemann, L.; Hoener, M. C., A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci. 2005, 26 (5), 274-281.
23. Raju, T. N., The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). Lancet 2000, 355 (9208), 1022-1022.
24. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J., Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2235.
25. Müller, G., Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today 2003, 8 (15), 681-691.
26. Guo, T.; Hobbs, D. W., Privileged structure-based combinatorial libraries targeting G protein-coupled receptors. Assay and drug development technologies 2003, 1 (4), 579-592.
27. Bywater, R. P., Privileged structures in GPCRs. Ernst Schering Foundation Symposium Proceedings 2006, (2), 75-91.
28. Gloriam, D. E.; Wellendorph, P.; Johansen, L. D.; Thomsen, A. R. B.; Pedersen, D. S.; Bräuner-Osborne, H., Chemogenomic Discovery of the First Selective Allosteric Antagonists at the GPRC6A Receptor. In Unpublished.
29. Snowden, M.; Green, D. V., The impact of diversity-based, high-throughput screening on drug discovery: chance favours the prepared mind. Current opinion in drug discovery & development 2008, 11 (4), 553-558.
30. Bleicher, K. H.; Green, L. G.; Martin, R. E.; Rogers-Evans, M., Ligand identification for G-protein-coupled receptors: a lead generation perspective. Curr. Opin. Chem. Biol. 2004, 8 (3), 287-296.
31. Jacoby, E.; Schuffenhauer, A.; Floersheim, P., Chemogenomics knowledge-based strategies in drug discovery. Drug News & Perspectives 2003, 16 (2), 93-93.
32. Jacoby, E., A Novel Chemogenomics Knowledge-Based Ligand Design Strategy-Application to G Protein-Coupled Receptors. Quant. Struct.-Act. Relat. 2001, 20 (2), 115-123.
33. Nordling, E.; Homan, E., Generalization of a targeted library design protocol: application to 5-HT7 receptor ligands. J. Chem. Inf. Comput. Sci. 2004, 44 (6), 2207-2215.
34. Klabunde, T.; Evers, A., GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. Chembiochem. 2005, 6 (5), 876-889.
35. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le, T. I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M., Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289 (5480), 739-745.
36. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C., High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318 (5854), 1258-1265.
37. Jaakola, V.-P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y. T.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C., The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322 (5905), 1211-1217.
38. Chien, E. Y. T.; Liu, W.; Zhao, Q.; Katritch, V. G.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C., Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist. Science 2010, 330 (6007), 1091-1095.
39. Wu, B.; Chien, E. Y. T.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C., Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists. Science 2010, 330 (6007), 1066-1071.
40. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G. W.; Tate, C. G.; Schertler, G. F. X., Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454 (7203), 486-491.
41. Andrews, G.; Jones, C.; Wreggett, K. A., An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol. Pharmacol. 2008, 73 (3), 855-867.
42. Dubus, E.; Ijjaali, I.; Barberan, O.; Petitet, F., Drug repositioning using in silico compound profiling. Future Medicinal Chemistry 2009, 1 (9), 1723-1736.
43. Garzya, V.; Forbes, I. T.; Gribble, A. D.; Hadley, M. S.; Lightfoot, A. P.; Payne, A. H.; Smith, A. B.; Douglas, S. E.; Cooper, D. G.; Stansfield, I. G.; Meeson, M.; Dodds, E. E.; Jones, D. N. C.; Wood, M.; Reavill, C.; Scorer, C. A.; Worby, A.; Riley, G.; Eddershaw, P.; Ioannou, C.; Donati, D.; Hagan, J. J.; Ratti, E. A., Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg. Med. Chem. Lett. 2007, 17 (2), 400-405.
44. Rocheville, M.; Garland, S. L., An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs. Drug Discovery Today: Technologies 2010, 7 (1), e87-e94.